The Drug Regulatory Authority of Pakistan (DRAP) has embarked on a digital transformation journey. The authority has successfully digitized the registration of 90,000 drugs and the licensing procedures for 650 pharmaceutical companies.
This pioneering step is poised to revolutionize the process for companies seeking to register or license new drugs, eliminating the need for physical visits to DRAP offices. The newly digitized system allows companies to apply for drug registration and licensing online, ushering in a new era of convenience and efficiency.
One of the notable advantages of this digital shift is the reduction of administrative burden, enabling a smoother and more expeditious approval process.
Companies can now navigate the registration and licensing procedures with greater ease and speed.
Notably, the digitized system extends its benefits to multinational companies, facilitating the streamlined registration and licensing of new drugs.
With DRAP registering an average of 6,000 to 7,000 new drugs annually and granting licenses to approximately 15 new pharmaceutical companies each year, the digital platform is expected to bring about a transformative impact.
This initiative aligns with DRAP’s commitment to enhancing efficiency, reducing delays, and promoting transparency within the pharmaceutical sector. By embracing digital processes, DRAP aims to create a more agile and responsive regulatory environment, fostering innovation and compliance.
As the pharmaceutical landscape undergoes this digital evolution, stakeholders anticipate a positive shift in the industry’s dynamics, ultimately contributing to a safer and more regulated healthcare ecosystem.
The digitization of drug registration and licensing is a testament to Pakistan’s commitment to advancing its regulatory framework for the greater benefit of public health.
